ArticleCureus2025
Highly Immunoresistant Acute Motor and Sensory Axonal Neuropathy With Concomitant Anti-NF155 Axonal Nodopathy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute motor and sensory axonal neuropathy (AMSAN) is a rare, severe subtype of Guillain-Barré syndrome (GBS) associated with a poorer prognosis and greater resistance to standard immunotherapies. While immunomodulatory therapies are the traditional mainstay therapies for GBS and its variants, as autoimmune-mediated processes, refractory cases can present unique challenges. In addition, chronic inflammatory demyelinating polyneuropathy (CIDP) is a known persistent variant of GBS with its own wide array of variations, including neurofascin IgG4-positive axonal nodopathy, associated with an antibody that provides an additional layer of immunoprotection. This condition has been found in previously documented case series to require non-traditional immunoregimens. We present a unique case of a highly refractory AMSAN with concomitant chronic axonal motor and sensory axonal nodopathy with high multimodal immunotherapy resistance. This case illustrates the importance of considering neurofascin IgG4 in refractory subacute axonal nodopathies and, consequently, the potential role of empiric rituximab, while also highlighting the need for further research into B-cell-depleting therapeutic alternatives in resistant cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.